Baird raised the firm’s price target on Definium Therapeutics (DFTX) to $37 from $16 and keeps an Outperform rating on the shares. The firm updated its model to include its DT120 in Major Depression Disorder potential.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DFTX:
- Definium Therapeutics price target raised to $36 from $20 at RBC Capital
- Psychedelic: Analyst initiates Atai Beckley with Buy rating
- Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry
- Definium Therapeutics: Advancing Late-Stage Psychedelic Pipeline and Diversifying Assets Underpin Buy Rating and $61 Target